Ely Lilly Gets Approval From FDA For Diabetes Drug

The FDA has granted approval for the sale and distribution of Jentadueto, a tablet designed to treat type-2 Diabetes. Jentadueto was made in a partnership between Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals, Inc.

The advantage of this product is that it can be taken as a single tablet taken twice daily. Lance Sloan, MD, of the Texas Institute for Kidney and Endocrine Disorders is optimistic that the new drug will provide immediate benefits.

“Most people with type 2 diabetes require more than one medication to help lower their blood sugar, due to the complex nature of type 2 diabetes. The approval of JENTADUETO is exciting because it combines two diabetes medications in a single tablet, making it a good option for people who need an additional medication, and for whom both linagliptin and metformin is appropriate.”

The new drug is appropriate only for patients with type 2 diabetes, not type 1 diabetes.